Abstract
In 2018, 9.6 million deaths from cancer were estimated, being this disease the second leading cause of death worldwide. Notwithstanding all the efforts developed in prevention, diagnosis and new treatment approaches, chemoresistance seems to be inevitable, leading to cancer progression, recurrence and affecting the outcome of the disease. As more and more evidence support that cancer is an evolutionary and ecological process, this concept is rarely applied in the clinical context. In fact, cancer cells emerge and progress within an ecological niche – the tumor microenvironment – that is shared with several other cell types and that is continuously changing. Therefore, the tumor microenvironment imposes several selective pressures on cancer cells such as acidosis, hypoxia, competition for space and resources, immune predation and anti-cancer therapies, that cancer cells must be able to adapt to or will face extinction.
In here, the role of the tumor microenvironment selective pressures on cancer progression will be discussed, as well as the targeting of its features/components as strategies to fight cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Achard C, Surendran A, Wedge M-E et al (2018) Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31:17–24. https://doi.org/10.1016/j.ebiom.2018.04.020
Agarwal M, Bhadauria AS (2013) A generalised prey-predator type model of immunogenic cancer with the effect of immunotherapy. Int J Eng Sci Technol 5:66–84. https://doi.org/10.4314/ijest.v5i1.6
Aktipis CA, Kwan VSY, Johnson KA et al (2011) Overlooking evolution: a systematic analysis of Cancer relapse and therapeutic resistance research. PLoS One 6:e26100. https://doi.org/10.1371/journal.pone.0026100
Aktipis CA, Boddy AM, Jansen G et al (2015) Cancer across the tree of life: cooperation and cheating in multicellularity. Philos Trans R Soc B Biol Sci 370:1–21. https://doi.org/10.1098/rstb.2014.0219
Albano G, Giorno V, Saturnino C (2007) A prey-predator model for immune response and drug resistance in tumor growth. In: Moreno Díaz R, Pichler FQAA (eds) Computer aided systems theory – EUROCAST 2007. Lecture notes in computer science, vol 4739. Springer, Berlin/Heidelberg, pp 171–178
Alexandre J, Batteux F, Nicco C et al (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48. https://doi.org/10.1002/ijc.21685
Alfarouk KO, Ibrahim ME, Gatenby RA, Brown JS (2013) Riparian ecosystems in human cancers. Evol Appl 6:46–53. https://doi.org/10.1111/eva.12015
Allen E, Ville PḾ, Warren CM et al (2016) Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep 15:1144–1160. https://doi.org/10.1016/j.celrep.2016.04.029
Angelova M, Mlecnik B, Vasaturo A et al (2018) Evolution of metastases in space and time under immune selection. Cell 175:751–765.e16. https://doi.org/10.1016/j.cell.2018.09.018
Archetti M, Ferraro DA, Christofori G (2015) Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc Natl Acad Sci U S A 112:1833–1838. https://doi.org/10.1073/pnas.1414653112
Axelrod R, Axelrod DE, Pienta KJ (2006) Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A 103:13474–13479. https://doi.org/10.1073/pnas.0606053103
Babbs CF (2012) Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. Am J Cancer Res 2:204–213
Balamurugan K (2016) HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer 138:1058–1066. https://doi.org/10.1002/ijc.29519
Barker HE, Paget JTE, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409–425. https://doi.org/10.1038/nrc3958
Bartosh TJ, Ullah M, Zeitouni S et al (2016) Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proc Natl Acad Sci U S A 113:E6447–E6456. https://doi.org/10.1073/pnas.1612290113
Bergman A, Gligorijevic B (2015) Niche construction game cancer cells play. Eur Phys J Plus 130:203–215. https://doi.org/10.1140/epjp/i2015-15203-5
Bhandari V, Hoey C, Liu LY et al (2019) Molecular landmarks of tumor hypoxia across cancer types. Nat Genet 51:308–318. https://doi.org/10.1038/s41588-018-0318-2
Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541–550. https://doi.org/10.1038/s41591-018-0014-x
Bray F, Ferlay J, Soerjomataram I et al (2018) Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Bristow RG, Hill RP (2008) Hypoxia and metabolism: hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180–192. https://doi.org/10.1038/nrc2344
Cairns J (1975) Mutation selection and the natural history of cancer. Nature 255:197–200. https://doi.org/10.1038/255197a0
Chang C-H, Qiu J, O’Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241. https://doi.org/10.1016/j.cell.2015.08.016
Chapman A, del Ama LF, Ferguson J et al (2014) Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep 8:688–695. https://doi.org/10.1016/j.celrep.2014.06.045
Chauhan VP, Chen IX, Tong R et al (2019) Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. Proc Natl Acad Sci 116:10674–10680. https://doi.org/10.1073/pnas.1819889116
Chen H, He X (2015) The convergent cancer evolution toward a single cellular destination. Mol Biol Evol 33:4–12. https://doi.org/10.1093/molbev/msv212
Chen H, Lin F, Xing K, He X (2015a) The reverse evolution from multicellularity to unicellularity during carcinogenesis. Nat Commun 6:1–9. https://doi.org/10.1038/ncomms7367
Chen Y, Zhang L, Liu W, Liu X (2015b) Prognostic significance of the tumor-stroma ratio in epithelial ovarian cancer. Biomed Res Int 2015:1–8. https://doi.org/10.1155/2015/589301
Chen H, Xu L, Li L et al (2018) Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Sci Rep 8:1–10. https://doi.org/10.1038/s41598-018-30417-6
Choi SYC, Collins CC, Gout PW, Wang Y (2013) Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol 230:350–355. https://doi.org/10.1002/path.4218
Cleary AS, Leonard TL, Gestl SA, Gunther EJ (2014) Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508:113–117. https://doi.org/10.1038/nature13187
Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 17:577–593. https://doi.org/10.1038/nrc.2017.77
Crespi B, Summers K (2005) Evolutionary biology of cancer. Trends Ecol Evol 20:545–552. https://doi.org/10.1016/j.tree.2005.07.007
Dagogo-Jack I, Shaw AT (2017) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81–94. https://doi.org/10.1038/nrclinonc.2017.166
Damaghi M, Tafreshi NK, Lloyd MC et al (2015) Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. Nat Commun 6:1–13. https://doi.org/10.1038/ncomms9752
Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM et al (2018) Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology 154:354–362. https://doi.org/10.1111/imm.12917
Darwin C (1859) The origin of species (text). Pennsylvania State University 448 p. https://doi.org/10.5117/9781904633785
Dasari S, Tchounwou BP (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. https://doi.org/10.1016/j.ejphar.2014.07.025
Datta M, Coussens LM, Nishikawa H et al (2019) Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ B 39:165–174. https://doi.org/10.1200/EDBK_237987
De Kruijf EM, Van Nes JGH, Van De Velde CJH et al (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125:687–696. https://doi.org/10.1007/s10549-010-0855-6
Denduluri SK, Idowu O, Wang Z et al (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2:13–25. https://doi.org/10.1016/j.gendis.2014.10.004
Di Gregorio A, Bowling S, Rodriguez TA (2016) Cell competition and its role in the regulation of cell fitness from development to cancer. Dev Cell 38:621–634. https://doi.org/10.1016/j.devcel.2016.08.012
Enriquez-Navas PM, Kam Y, Das T et al (2016) Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med 8:1–9. https://doi.org/10.1126/scitranslmed.aad7842
Fais S, Overholtzer M (2018) Cell-in-cell phenomena in cancer. Nat Rev Cancer 18:758–766. https://doi.org/10.1038/s41568-018-0073-9
Fitzgerald DM, Hastings PJ, Rosenberg SM (2017) Stress-induced mutagenesis: implications in cancer and drug resistance. Ann Rev Cancer Biol 1:119–140. https://doi.org/10.1146/annurev-cancerbio-050216-121919
Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527. https://doi.org/10.1001/jamaoncol.2015.0735
Fortunato A, Boddy A, Mallo D et al (2017) Natural selection in cancer biology: from molecular snowflakes to trait hallmarks. Cold Spring Harb Perspect Med 7:1–14. https://doi.org/10.1101/cshperspect.a029652
Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016–1036
Gallaher JA, Enriquez-Navas PM, Luddy KA et al (2017) Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. bioRxiv:1–21. https://doi.org/10.1101/128959
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899. https://doi.org/10.1038/nrc1478
Gatenby RA, Smallbone K, Maini PK et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646–653. https://doi.org/10.1038/sj.bjc.6603922
Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894–4903. https://doi.org/10.1158/0008-5472.CAN-08-3658
Gillies RJ, Verduzco D, Gatenby RA (2012) Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12:487–493. https://doi.org/10.1038/nrc3298
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32:1267–1284. https://doi.org/10.1101/gad.314617.118
Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306–313. https://doi.org/10.1038/nature10762
Gu H, Huang T, Shen Y et al (2018) Reactive oxygen species-mediated tumor microenvironment transformation: the mechanism of radioresistant gastric Cancer. Oxidative Med Cell Longev 2018:1–8. https://doi.org/10.1155/2018/5801209
Guillaumond F, Leca J, Olivares O et al (2013) Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci 110:3919–3924. https://doi.org/10.1073/pnas.1219555110
Gupta S, Roy A, Dwarakanath BS (2017) Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Front Oncol 7:1–24. https://doi.org/10.3389/fonc.2017.00068
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322. https://doi.org/10.1016/j.ccr.2012.02.022
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70. https://doi.org/10.1007/s00262-010-0968-0
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hicks KC, Knudson KM, Jones FR, et al (2018, April 14–18) Abstract 1740: epigenetic reprogramming of the tumor microenvironment by entinostat increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade. In: AACR annual meeting 2018. Chicago, p 1740
Ibrahim-Hashim A, Gillies RJ, Brown JS, Gatenby RA (2017) Coevolution of tumor cells and their microenvironment: “niche construction in Cancer” In: Ujvari B, Roche B, Thomas F (eds) Ecology and evolution of cancer. Elsevier Inc., pp 111–117
Jiménez-Sánchez A, Memon D, Pourpe S et al (2017) Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170:927–938.e20. https://doi.org/10.1016/j.cell.2017.07.025
Jo Y, Choi N, Kim K et al (2018) Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development. Theranostics 8:5259–5275. https://doi.org/10.7150/thno.29098
Karpathiou G, Vieville M, Gavid M et al (2019) Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Head Neck 41:1918–1927. https://doi.org/10.1002/hed.25629
Kartal S (2014) Mathematical modeling and analysis of tumor-immune system interaction by using Lotka-Volterra predator-prey like model with piecewise constant arguments. Period Eng Nat Sci 2:7–12. https://doi.org/10.21533/pen.v2i1.36
Kaur G, Ahmad N (2014) On study of immune response to tumor cells in prey-predator system. Int Sch Res Not 2014:1–8. https://doi.org/10.1155/2014/346597
Kemi N, Eskuri M, Herva A et al (2018) Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer 119:435–439. https://doi.org/10.1038/s41416-018-0202-y
Korobeinikova A, Starkovc KE, Valle PA (2017) Modeling cancer evolution: evolutionary escape under immune system control. J Phys Conf Ser 811:012004–012012. https://doi.org/10.1088/1742-6596/811/1/012004
Koshiji M, To KKW, Hammer S et al (2005) HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol Cell 17:793–803. https://doi.org/10.1016/j.molcel.2005.02.015
Lacina L, Čoma M, Dvořánková B et al (2019) Evolution of Cancer progression in the context of Darwinism. Anticancer Res 39:1–16. https://doi.org/10.21873/anticanres.13074
Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670–691. https://doi.org/10.1016/j.cell.2016.11.037
Leong SP, Aktipis A, Maley C (2018) Cancer initiation and progression within the cancer microenvironment. Clin Exp Metastasis 35:361–367. https://doi.org/10.1007/s10585-018-9921-y
Levayer R (2019) Solid stress, competition for space and cancer: the opposing roles of mechanical cell competition in tumour initiation and growth. Semin Cancer Biol:1–12. https://doi.org/10.1016/j.semcancer.2019.05.004
Li C, Little JB, Hu K (2001) Persistent genetic instability in Cancer cells induced by non-DNA-damaging stress exposures advances in brief persistent genetic instability in cancer cells induced by non-DNA-damaging. Cancer Res 61:428–432
Liu J, Liu J, Li J et al (2014) Tumor–stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol Oncol 132:81–86. https://doi.org/10.1016/j.ygyno.2013.11.003
Lopes-Coelho F, André S, Félix A, Serpa J (2018) Breast cancer metabolic cross-talk: fibroblasts are hubs and breast cancer cells are gatherers of lipids. Mol Cell Endocrinol 462:93–106. https://doi.org/10.1016/j.mce.2017.01.031
Lugini L, Matarrese P, Tinari A et al (2006) Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 66:3629–3638. https://doi.org/10.1158/0008-5472.CAN-05-3204
Luoto KR, Kumareswaran R, Bristow RG (2013) Tumor hypoxia as a driving force in genetic instability. Genome Integr 4:1–15. https://doi.org/10.1186/2041-9414-4-5
Lyssiotis CA, Kimmelman AC (2017) Metabolic interactions in the tumor microenvironment. Trends Cell Biol 27:863–875. https://doi.org/10.1016/j.tcb.2017.06.003
Maacha S, Bhat AA, Jimenez L et al (2019) Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer 18:1–16. https://doi.org/10.1186/s12943-019-0965-7
Maley CC, Aktipis A, Graham TA et al (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605–619. https://doi.org/10.1038/nrc.2017.69
Mansoori B, Mohammadi A, Davudian S et al (2017) The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 7:339–348. https://doi.org/10.15171/apb.2017.041
Martín-Pardillos A, Valls-Chiva A, Serrano EB, et al (2018, April 14–18) Abstract 2183: clonal cooperation in cancer progression: a new paradigm in cancer. In: AACR annual meeting 2018. Chicago. p 2183
Marullo R, Werner E, Degtyareva N et al (2013) Cisplatin induces a mitochondrial-ros response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8:1–15. https://doi.org/10.1371/journal.pone.0081162
McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613–628. https://doi.org/10.1016/j.cell.2017.01.018
Merlo LMF, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924–935. https://doi.org/10.1038/nrc2013
Miller BE, Miller FR, Wilburn D, Heppner GH (1988) Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res 48:5747–5753
Milo I, Bedora-Faure M, Garcia Z et al (2018) The immune system profoundly restricts intratumor genetic heterogeneity. Sci Immunol 3:1–14. https://doi.org/10.1126/sciimmunol.aat1435
Nagraj J, Mukherjee S, Chowdhury R (2015) Cancer: an evolutionary perspective. J Cancer Biol Res 3:1064–1068
Nakazawa MS, Keith B, Simon MC (2016) Oxygen availability and metabolic adaptations. Nat Rev Cancer 16:663–673. https://doi.org/10.1038/nrc.2016.84
Niehr F, Eder T, Pilz T et al (2018) Multilayered omics-based analysis of a head and neck Cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection. Clin Cancer Res 24:158–168. https://doi.org/10.1158/1078-0432.CCR-17-2410
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28. https://doi.org/10.1126/science.191.4224.241-a
Odunsi K (2018) Abstract IA22: reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy. In: AACR special conference: addressing critical questions in ovarian Cancer research and treatment; October 1-4, 2017; Pittsburgh, PA. p IA22
Ovens K, Naugler C (2012) Preliminary evidence of different selection pressures on cancer cells as compared to normal tissues. Theor Biol Med Model 9:44–54. https://doi.org/10.1186/1742-4682-9-44
Paolicchi E, Gemignani F, Krstic-Demonacos M et al (2016) Targeting hypoxic response for cancer therapy. Oncotarget 7:13464–13478. https://doi.org/10.18632/oncotarget.7229
Pellegrini P, Serviss JT, Lundbäck T et al (2018) A drug screening assay on cancer cells chronically adapted to acidosis. Cancer Cell Int 18:1–15. https://doi.org/10.1186/s12935-018-0645-5
Pepper JW, Scott Findlay C, Kassen R et al (2009) Cancer research meets evolutionary biology. Evol Appl 2:62–70. https://doi.org/10.1111/j.1752-4571.2008.00063.x
Pillai SR, Damaghi M, Marunaka Y et al (2019) Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev 38:205–222. https://doi.org/10.1007/s10555-019-09792-7
Pisarsky L, Bill R, Fagiani E et al (2016) Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep 15:1161–1174. https://doi.org/10.1016/j.celrep.2016.04.028
Qian JJ, Akçay E (2018) Competition and niche construction in a model of cancer metastasis. PLoS One 13:1–20. https://doi.org/10.1371/journal.pone.0198163
Rankin EB, Giaccia AJ (2016) Hypoxic control of metastasis. Science 352:175–180. https://doi.org/10.1126/science.aaf4405
Reynolds TV, Rockwell S, Gazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56:5754–5757
Riemann A, Reime S, Thews O (2017) Tumor acidosis and hypoxia differently modulate the inflammatory program: measurements in vitro and in vivo. Neoplasia 19:1033–1042. https://doi.org/10.1016/j.neo.2017.09.005
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR (2019) Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20:1–31. https://doi.org/10.3390/ijms20040840
Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207–214. https://doi.org/10.1016/j.tips.2012.01.005
Senthebane DA, Rowe A, Thomford NE et al (2017) The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci 18:1–30. https://doi.org/10.3390/ijms18071586
Senthebane DA, Jonker T, Rowe A et al (2018) The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices. Int J Mol Sci 19:1–32. https://doi.org/10.3390/ijms19102861
Son B, Lee S, Youn H et al (2017) The role of tumor microenvironment in therapeutic resistance. Oncotarget 8:3933–3945. https://doi.org/10.18632/oncotarget.13907
Sun D, Dalin S, Hemann MT et al (2016) Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep 6:1–13. https://doi.org/10.1038/srep36198
Tafani M, Sansone L, Limana F et al (2016) The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxidative Med Cell Longev 2016:1–18. https://doi.org/10.1155/2016/3907147
Tang L, Wei F, Wu Y et al (2018) Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res 37:1–15. https://doi.org/10.1186/s13046-018-0758-7
Toth RK, Warfel NA (2017) Strange bedfellows: nuclear factor, erythroid 2-like 2 (Nrf2) and hypoxia-inducible factor 1 (HIF-1) in tumor hypoxia. Antioxidants (Basel, Switzerland) 6:1–21. https://doi.org/10.3390/antiox6020027
van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM et al (2018) Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch 473:405–412. https://doi.org/10.1007/s00428-018-2408-z
Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239. https://doi.org/10.1007/s10555-007-9055-1
Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. Cold Spring Harb Perspect Med 7:1–16. https://doi.org/10.1101/cshperspect.a026617
Wang k, Ma W, Wang J et al (2012) Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 7:1457–1461. https://doi.org/10.1097/JTO.0b013e318260dfe8
Wigerup C, Påhlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152–169. https://doi.org/10.1016/j.pharmthera.2016.04.009
Wojtkowiak JW, Rothberg JM, Kumar V et al (2012) Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res 72:3938–3947. https://doi.org/10.1158/0008-5472.CAN-11-3881
Wu TS, Lin BR, Chang HH (2015) Radio resistance mechanisms of cancers: an overview and future perspectives. Biol Med s2:1–7. https://doi.org/10.4172/0974-8369.1000s2-003
Yu Y, Cui J (2018) Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol Lett 16:4105–4113. https://doi.org/10.3892/ol.2018.9219
Zhang X-L, Jiang C, Zhang Z-X et al (2014) The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat 37:480–484. https://doi.org/10.1159/000365165
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (2017) Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun 8:1–9. https://doi.org/10.1038/s41467-017-01968-5
Zhou J, Schmid T, Schnitzer S, Brüne B (2006) Tumor hypoxia and cancer progression. Cancer Lett 237:10–21. https://doi.org/10.1016/j.canlet.2005.05.028
Acknowledgments
The authors acknowledge iNOVA4Health – UID/Multi/04462/2013, a program financially supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nunes, S.C. (2020). Tumor Microenvironment – Selective Pressures Boosting Cancer Progression. In: Serpa, J. (eds) Tumor Microenvironment . Advances in Experimental Medicine and Biology, vol 1219. Springer, Cham. https://doi.org/10.1007/978-3-030-34025-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-34025-4_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34024-7
Online ISBN: 978-3-030-34025-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)